Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme (Q38112074)

29 August 2017

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme (English)

1 reference

29 August 2017

1 reference

Bryant England

1

1 reference

29 August 2017

Tiangui Huang

series ordinal

2

1 reference

29 August 2017

Michael Karsy

series ordinal

3

1 reference

29 August 2017

language of work or name

1 reference

5 June 2013

1 reference

29 August 2017

1 reference

29 August 2017

34

1 reference

29 August 2017

4

1 reference

29 August 2017

2063-2074

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-013-0871-3

29 August 2017

0 references

cites work

Genetic profile of astrocytic and oligodendroglial gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

TP53: a key gene in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 suppresses the self-renewal of adult neural stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 regulates the self-renewal and differentiation of neural precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Rescuing the function of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Blinded by the Light: The Growing Complexity of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Transcriptional control of human p53-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Cytoplasmic functions of the tumour suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Ubiquitination and degradation of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The guardian's little helper: microRNAs in the p53 tumor suppressor network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

microRNA-34a is tumor suppressive in brain tumors and glioma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Transcription regulation by mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Structural biology of the p53 tumour suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Structural biology of the tumor suppressor p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The isoforms of the p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Molecular control of brain size: regulators of neural stem cell life, death and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Mutant p53: an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The origins and evolution of the p53 family of genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

High affinity MAR-DNA binding is a common property of murine and human mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-->Ser) in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Mutant p53 proteins bind DNA in a DNA structure-selective mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Oncogenomic Approaches in Exploring Gain of Function of Mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Modulation of gene expression by tumor-derived p53 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Stem cells: The promises and perils of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Linking the p53 tumour suppressor pathway to somatic cell reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Immortalization eliminates a roadblock during cellular reprogramming into iPS cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The Ink4/Arf locus is a barrier for iPS cell reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 Regulates LIF expression in human medulloblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Tumor spectrum analysis in p53-mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 increases experimental metastatic capacity of murine carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Cancer stem cells and "stemness" genes in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 mutation heterogeneity in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Neuronal or glial progeny: regional differences in radial glia fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Neural stem cells in mammalian development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The multistep nature of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Gene expression profiling and genetic markers in glioblastoma survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Long-term survival with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

IDH mutations in glioma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Shaping genetic alterations in human cancer: the p53 mutation paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

The p53 mutation "gradient effect" and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

High metastatic potential in mice inheriting a targeted p53 missense mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

p53 isoforms can regulate p53 transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Mutant p53 targeting by the low molecular weight compound STIMA-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0871-3

Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme

21 January 2018

1 reference

12 December 2020

What is the clinical value of cancer stem cell markers in gliomas?

1 reference

12 December 2020

p53 and human cancer: the first ten thousand mutations.

1 reference

12 December 2020

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

1 reference

12 December 2020

Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.

1 reference

12 December 2020

Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results

1 reference

12 December 2020

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

1 reference

12 December 2020

p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3

1 reference

12 December 2020

p53, p63 and p73--solos, alliances and feuds among family members

1 reference

12 December 2020

Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family

1 reference

12 December 2020

All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner

1 reference

12 December 2020

Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.

1 reference

12 December 2020

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer

1 reference

12 December 2020

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants

1 reference

12 December 2020

DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development

1 reference

12 December 2020

Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice

1 reference

12 December 2020

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

1 reference

12 December 2020

Pharmacological rescue of mutant p53 conformation and function

1 reference

12 December 2020

Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features.

1 reference

12 December 2020

10.1007/S13277-013-0871-3

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference